8-K: NEXGEL Reports Record 2023 Revenue Growth Driven by Strategic Partnerships and Branded Products

NEXGEL achieved a 99.7% year-over-year revenue increase in 2023, reaching $4.1 million, fueled by growth in both branded products and contract manufacturing.

Summary

• NEXGEL reported a significant revenue increase for the full year 2023, reaching $4.1 million, a 99.7% increase compared to $2 million in 2022.
• The revenue growth was primarily driven by a 166% increase in contract manufacturing sales and a 52.4% increase in branded product revenue, which reached $1.24 million.
• For the fourth quarter of 2023, revenue totaled $1.1 million, a 110% increase compared to $524 thousand in the same period of 2022.
• Branded product revenue for the fourth quarter was $392,000, a 104.2% year-over-year increase and a 10.1% sequential increase.
• Gross profit for the year was $619 thousand, compared to $256 thousand in 2022, with a gross profit margin of 15.2% compared to 12.5% in the previous year.
• The company's net loss for 2023 was $3.2 million, an improvement from the $4.7 million loss in 2022.
• NEXGEL ended the year with $2.7 million in cash and subsequently raised an additional $1 million through a registered direct offering.
• The company expects first quarter 2024 revenue of $1.25 million, which includes a full quarter of revenue from the Kenkoderm acquisition.

Sentiment

Score: 8

Explanation: The document presents a very positive outlook with strong revenue growth, strategic partnerships, and improved financial metrics. The company's future outlook is also optimistic, suggesting a high level of confidence in its growth trajectory.

Positives

• NEXGEL experienced substantial revenue growth, nearly doubling year-over-year.
• The company's gross profit margin improved, indicating better profitability on sales.
• Net losses decreased significantly compared to the previous year.
• Strategic partnerships with major companies like AbbVie and STADA were established.
• The acquisition of Kenkoderm expands the company's product portfolio.
• The company has expanded its manufacturing capacity to meet growing demand.
• The company has reduced interest expense by paying off convertible notes.
• The company has a strong cash position of $2.7 million at the end of 2023, with an additional $1 million raised subsequently.

Negatives

• Despite significant revenue growth, the company still reported a net loss of $3.2 million for the year.
• Selling, general, and administrative expenses increased by 23.4% to $4.0 million.
• Cost of revenues increased by 93.6% to $3.5 million, aligning with the increased revenues.
• Research and development expenses decreased due to the completion of certain studies.

Risks

• The company's continued reliance on strategic partnerships for growth could pose a risk if these partnerships are not successful.
• Increased operating expenses could impact profitability if not managed effectively.
• The company's ability to scale production to meet growing demand from strategic partnerships is crucial.
• The company's future performance is subject to various market and economic risks.

Future Outlook

The company expects first quarter 2024 revenue of $1.25 million, reflecting a full quarter of revenue contribution from the Kenkoderm acquisition but excluding a $176,000 non-refundable deposit from Abbvie for their first order. The company anticipates significant growth going forward based on strategic partnerships and operational improvements.

Management Comments

• 2023 was a record year for NEXGEL and transformational in many respects.
• Our nearly 100% year-over-year revenue growth in 2023 was primarily driven by our branded products and contract manufacturing.
• We have the right product, operational expertise and balance sheet to execute on the multiple growth levers we have including our agreements with Abbvie and STADA.

Industry Context

The announcement reflects a positive trend in the healthcare and consumer product sectors, where companies are increasingly focusing on strategic partnerships and product diversification to drive growth. NEXGEL's focus on hydrogel technology positions it well in the market for advanced wound care and skincare products.

Comparison to Industry Standards

• NEXGEL's revenue growth of 99.7% year-over-year is significantly higher than the average growth rate for many companies in the medical device and consumer health sectors, which typically see single-digit or low double-digit growth.
• Companies like 3M and Johnson & Johnson, which also operate in the healthcare and consumer product space, often have more established revenue streams but may not experience such rapid growth rates in specific product lines.
• The gross profit margin of 15.2% is relatively low compared to some established players in the industry, which can have margins of 30% or higher, indicating that NEXGEL may have room to improve its cost structure as it scales.
• The company's strategic partnerships with AbbVie and STADA are similar to strategies employed by other companies in the sector to expand market reach and product distribution.

Stakeholder Impact

• Shareholders will likely view the strong revenue growth and improved financial performance positively.
• Employees may benefit from the company's growth and expansion.
• Customers will have access to a wider range of products through the company's strategic partnerships.
• Suppliers may see increased demand for their products due to the company's growth.
• Creditors may view the company's improved financial position favorably.

Next Steps

• The company will continue to focus on expanding its strategic partnerships.
• NEXGEL will continue to scale its manufacturing operations to meet growing demand.
• The company will focus on the distribution and commercialization of consumer health OTC products in North America in 2024.
• Management will host a conference call to discuss the results.

Key Dates

Keywords

hydrogel, contract manufacturing, branded products, revenue growth, strategic partnerships, healthcare, consumer products, financial results, acquisition, distribution